Acupuncture Feasibility Trial for Dyspnea in Lung Cancer
This is a single arm clinical trial to establish the feasibility of conducting a clinical trial of acupuncture in reducing dyspnea among lung cancer survivors who have completed chemoradiotherapy. Twelve subjects with dyspnea will be recruited to this clinical trial. Up to 10 sessions of acupuncture will be delivered over the course of 8-10 weeks. The primary outcome will be dyspnea as measured by the English version of the Cancer Dyspnea Scale at the completion of the intervention.
Checked against the public recordLast updated Jul 23, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Interventions being studied
- Procedure: Acupuncture
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of Lung Cancer (Non small cell and small cell both eligible) * Completion of concurrent CRT at least 6 months prior to randomization. * Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level) * Ability to understand written English -Willingness to adhere to all study-related procedures * Age 18 years old * ECOG Performance Status 1-3 Exclusion Criteria: * Current receipt of therapy for treatment related pneumonitis for 3 weeks. * Surgical resection of this LC (lobectomy or pneumonectomy) * Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL) * Current bleeding disorder by history * Life expectancy of 12 weeks, as assessed by primary oncologist
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 23, 2019. Always confirm current availability with the study team.